Combination with gamma secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF mutant melanoma cells

被引：0
|
作者：
Zhu, G. [1 ,2 ]
Yi, X. [1 ]
Haferkamp, S. [3 ]
Hesbacher, S. [2 ]
Li, C. [1 ]
Goebeler, M. [2 ]
Gao, T. [1 ]
Houben, R. [2 ]
Schrama, D. [2 ]
机构：
[1] Fourth Mil Med Univ, Dermatol, Xian, Peoples R China
[2] Univ Hosp Wurzburg, Dermatol, Wurzburg, Germany
[3] Univ Regensburg, Dermatol, Regensburg, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 05期
关键词：
D O I：
10.1016/j.jid.2016.02.699
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
658
引用
收藏
页码：S116 / S116
页数：1
相关论文
共 50 条
  • [1] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Schrama, D.
    Zhu, G.
    Goebeler, M.
    Houben, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 26 - 27
  • [2] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Schrama, D.
    Zhu, G.
    Goebeler, M.
    Houben, R.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E93 - E93
  • [3] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Zhu, Guannan
    Yi, Xiuli
    Haferkamp, Sebastian
    Hesbacher, Sonja
    Li, Chunying
    Goebeler, Matthias
    Gao, Tianwen
    Houben, Roland
    Schrama, David
    CANCER LETTERS, 2016, 376 (01) : 43 - 52
  • [4] Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
    Sabbatino, Francesco
    Wang, Yangyang
    Scognamiglio, Giosue
    Favoino, Elvira
    Feldman, Steven A.
    Villani, Vincenzo
    Flaherty, Keith T.
    Nota, Sjoerd
    Giannarelli, Diana
    Simeone, Ester
    Anniciello, Anna M.
    Palmieri, Giuseppe
    Pepe, Stefano
    Botti, Gerardo
    Ascierto, Paolo A.
    Ferrone, Cristina R.
    Ferrone, Soldano
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (07):
  • [5] Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
    Hamid, Omid
    Cowey, C. Lance
    Offner, Michelle
    Faries, Mark
    Carvajal, Richard D.
    CANCERS, 2019, 11 (11)
  • [6] Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma
    Sabbatino, Francesco
    Wang, Yangyang
    Scognamiglio, Giosue
    Favoino, Elvira
    Feldman, Steven A.
    Villani, Vincenzo
    Flaherty, Keith T.
    Nota, Sjoerd
    Giannarelli, Diana
    Simeone, Ester
    Anniciello, Anna M.
    Palmieri, Giuseppe
    Pepe, Stefano
    Botti, Gerardo
    Ascierto, Paolo A.
    Ferrone, Cristina R.
    Ferrone, Soldano
    CANCER RESEARCH, 2016, 76
  • [7] Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
    Kim, Jae-Hyeon
    Ahn, Jun-Ho
    Lee, Michael
    CANCER RESEARCH AND TREATMENT, 2017, 49 (04): : 947 - 959
  • [8] Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
    Romano, Gabriele
    Paradiso, Francesca
    Li, Peng
    Shukla, Pooja
    Barger, Lindsay
    El Naggar, Olivia
    Miller, John P.
    Liang, Roger J.
    Helms, Timothy L.
    Wargo, Jennifer A.
    Taraballi, Francesca
    Costello, James C.
    Kwong, Lawrence N.
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
    Romano, Gabriele
    Paradiso, Francesca
    Li, Peng
    Shukla, Pooja
    Barger, Lindsay N.
    El Naggar, Olivia
    Miller, John P.
    Liang, Roger J.
    Helms, Timothy L.
    Lazar, Alexander J.
    Wargo, Jennifer A.
    Taraballi, Francesca
    Costello, James C.
    Kwong, Lawrence N.
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (05) : 558 - 569
  • [10] Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
    Mak, Gabriel
    Arkenau, Hendrik-Tobias
    Chin, Melvin
    MELANOMA RESEARCH, 2014, 24 (04) : 408 - 412
12345